These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34737196)

  • 21. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
    Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
    Painter GR; Natchus MG; Cohen O; Holman W; Painter WP
    Curr Opin Virol; 2021 Oct; 50():17-22. PubMed ID: 34271264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
    Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
    Abdelnabi R; Foo CS; De Jonghe S; Maes P; Weynand B; Neyts J
    J Infect Dis; 2021 Sep; 224(5):749-753. PubMed ID: 34244768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of molnupiravir for COVID-19 patients.
    Fatima M; Azeem S; Saeed J; Shahid A; Cheema HA;
    Eur J Intern Med; 2022 Aug; 102():118-121. PubMed ID: 35649740
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational Analysis of Molnupiravir.
    Sharov AV; Burkhanova TM; Taskın Tok T; Babashkina MG; Safin DA
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of antivirals against SARS-CoV-2.
    Sidebottom DB; Smith DD; Gill D
    BMJ; 2021 Oct; 375():n2611. PubMed ID: 34711614
    [No Abstract]   [Full Text] [Related]  

  • 32. Molnupiravir's authorisation was premature.
    Brophy JM
    BMJ; 2022 Mar; 376():o443. PubMed ID: 35241455
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Nanopore Based Molnupiravir Sensor.
    Jia W; Hu C; Wang Y; Zhang P; Chen HY; Huang S
    ACS Sens; 2022 May; 7(5):1564-1571. PubMed ID: 35427117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
    J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
    Jonsdottir HR; Siegrist D; Julien T; Padey B; Bouveret M; Terrier O; Pizzorno A; Huang S; Samby K; Wells TNC; Boda B; Rosa-Calatrava M; Engler OB; Constant S
    Biomed Pharmacother; 2022 Jun; 150():113058. PubMed ID: 35658229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d.
    Sacks HS
    Ann Intern Med; 2022 Apr; 175(4):JC40. PubMed ID: 35377719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
    Kulkarni P; Padmanabhan S
    Biotechnol Lett; 2022 Jul; 44(7):831-843. PubMed ID: 35608787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-generation oral antivirals against SARS-CoV-2.
    Sendi P; Razonable RR; Nelson SB; Soriano A; Gandhi RT
    Clin Microbiol Infect; 2022 Sep; 28(9):1230-1235. PubMed ID: 35545195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.